Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 12/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377533 | 0.91 | HSD17B10 (0.47) | HSD17B10NAMPTCYP2C9IDH1CA1 | |
| SCHEMBL19377410 | 0.86 | HSD17B10 (0.46) | HSD17B10ACACBNAMPTCYP2C9IDH1 | |
| SCHEMBL19377344 | 0.83 | ACACB (0.43) | HSD17B10ACACBNAMPTCYP2C9IDH1 | |
| SCHEMBL19377435 | 0.78 | HSD17B10 (0.46) | HSD17B10ACACBNAMPTCYP2C9IDH1 | |
| SCHEMBL19377439 | 0.76 | HSD17B10 (0.46) | HSD17B10NAMPTCYP2C9IDH1CA1 | |
| SCHEMBL19377183 | 0.75 | HSD17B10 (0.48) | HSD17B10NAMPTCYP2C9IDH1CA1 | |
| SCHEMBL19377210 | 0.75 | HSD17B10 (0.48) | HSD17B10NAMPTCYP2C9IDH1CA1 | |
| SCHEMBL19377317 | 0.75 | HSD17B10 (0.48) | HSD17B10NAMPTCYP2C9IDH1CA1 | |
| SCHEMBL19377402 | 0.75 | KMT2A (0.45) | HSD17B10ACACBNAMPTCYP2C9IDH1 | |
| SCHEMBL19377477 | 0.75 | HSD17B10 (0.43) | HSD17B10NAMPTCYP2C9IDH1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | HSD17B10 2852/4885ACACB 2049/4885NAMPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.